The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Subscribe To Our Newsletter & Stay Updated
